维普期刊资源整合服务平台（V6.5）

272篇 您的检索式：作者名="Galipeau"

选中清除导出查看参考文献查看引证文献引用追踪共14页首页上一页第1页下一页末页 /14 跳转

	题名	作者	年代	出处	被引量
1	Plasminogen kringle 5-engineered glioma cells block migration of tumor- associated macrophages and suppress tumor vascularization and progres- sion.显示文摘	Perri SR Nalbantoglu J Annabi B Koty Z Lejeune L Francois M Di Falco MR Beliveau R Galipeau J	2005	中国神经肿瘤杂志2005，3，3：	8
2	Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease显示文摘Utilization of mesenchymal stromal cells(MSCs) for the treatment of Crohn's disease and ulcerative colitis is of translational interest.Safety of MSC therapy has been well demonstrated in early phase clinical trials but efficacy in randomized clinical trials needs to be demonstrated.Understanding MSC mechanisms of action to reduce gut injury and inflammation is necessary to improve current ongoing and future clinical trials.However, two major hurdles impede the direct translation of data derived from animal experiments to the clinical situation:(1) limitations of the currently available animal models of colitis that reflect human inflammatory bowel diseases(IBD).The etiology and progression of human IBD are multifactorial and hence a challenge to mimic in animal models; and(2) Species specific differences in the functionality of MSCs derived from mice versus humans.MSCs derived from mice and humans are not identical in their mechanisms of action in suppressing inflammation.Thus, preclinical animal studies with murine derived MSCs cannot be considered as an exact replica of human MSC based clinical trials.In the present review, we discuss the therapeutic properties of MSCs in preclinical and clinical studies of IBD.We also discuss the challenges and approaches of using appropriate animal models of colitis, not only to study putative MSC therapeutic efficacy and their mechanisms of action, but also the suitability of translating findings derived from such studies to the clinic.	Raghavan Chinnadurai Spencer Ng Vijayakumar Velu Jacques Galipeau	2015	World Journal of Gastroenterology2015，21，16：	6
3	Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression显示文摘	Brian J Reid Laura J Prevo Patricia C Galipeau Carissa A Sanchez Gary Longton Douglas S Levine Patricia L Blount Peter S Rabinovitch	2001	The American Journal of Gastroenterology2001，，10：	2
4	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages 显示文摘	Wang JS Shum-Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，5：	1
5	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages显示文摘	Wang JS Shum-Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，5：	1
6	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages显示文摘	Wang JS Shum-Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，：	1
7	Marrow stromal cells for cellar cardiomyoplasty:feasibility and potential clinical advantages显示文摘	Wang JS Tim DS Galipeau J	2000	Thorac Cardiovasc Surg2000，120，8：	1
8	A study of low-cost sensors for measuring low relative humidity 显示文摘	Story P R Galipeau D W Mileham R D	1995	Sensors andActuatorsB: Chemical1995，25，13：	1
9	Marrow stromal cells for cellular cardiomyoplasty: Feasibility and potential clinical advantages显示文摘	Shum - Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，5：	1
10	Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells显示文摘	Allay J A Galipeau J Blakley R L	1998	Stem Cells1998，16，1：	1
11	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages显示文摘	Wang JS Shum-Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，5：	1
12	Marrow stromal cells for cellular cardiomvoplasty: feasibility and potential clinical advantages 显示文摘	Wang JS Shum-Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，5：	1
13	p53-mutant clones and field effects in barrett's esophagus1显示文摘	Laura J Prevo Carissa A Sanchez Patricia C Galipeau	1999	Cancer Research1999，59，19：	1
14	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages 显示文摘	Wang JS Shum-Tim Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，：	1
15	Marrow stromal cells for cellular cardiom yoplasty, feasibility and potential clinical advantages显示文摘	Wang JS Shum Tim D Galipeau J	2000	J Thorac Cardiovase Surg2000，120，5：	1
16	Marrow mesenchymal stem cells for celludar cardiomyoplasty:feasibility and potential clinical advantages显示文摘	Wang JS Shum TD Galipeau J	2000	Thorac Cardiovasc Surg2000，120，：	1
17	Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages显示文摘	Wang JS Shurn Tim D Galipeau J		0，，：	1
18	Marrow stromal cells for celluar cardiomyoplasty: feasibility and potential clinical advantages显示文摘	Wang JS hum- Tim D Galipeau J	2000	J Thorac Cardiovasc Surg2000，120，5：	1
19	Vesicular atomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer显示文摘	Galipeau J Li H Paquim A	1999	Cancer Res1999，59，10：	1
20	Vesicular stomatitis virus G pseudotyped retrovector mediates effective in vivo suicide gene delivery in experimental brain cancer 显示文摘	Galipeau J Li H Paquin A	1999	Cancer Res1999，59，10：	1

返回顶部每页显示：

共14页首页上一页第1页下一页末页 /14 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示